GS 9688

Drug Profile

GS 9688

Alternative Names: GS-9688

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 06 Dec 2016 Preclinical trials in Hepatitis B in New Zealand (PO) (ACTRN12616001646437p) before October 2016
  • 06 Dec 2016 Gilead Sciences plans a phase I trial for Hepatitis B (In volunteers) in New Zealand (ACTRN12616001646437p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top